Across TCGA pan-cancer cohorts, ADH1A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADH1A data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ADH1A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ADH1A expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where ADH1A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.245	0.853	.002	22	view →
LUAD	DFS	Median	All	0.747	0.407	.002	19	view →
UCEC	OS	Median	II,III,IV	0.554	0.904	.029	8	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.316	.006	7	view →
CCRCC	DFS	Median	All	0.831	0.622	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ADH1A tumor-vs-normal RNA expression · all ADH1A data types